Table 4.
Time to progression (TTP) of metastatic melanoma and renal cell carcinoma (RCC) patients vaccinated with dendritic cell–tumor cell hybrids every 6 weeks until disease progression or lack of tumor cells for vaccine preparation. OR objective response, SD Stable disease, DP disease progression
Response | Melanoma | RCC | ||
---|---|---|---|---|
n | TTPa | n | TTP | |
OR | 0 | – | 3 | 6.7 (5–21) |
SD | 8 | 11.1 (4–17+) | 14 | 8.4 (3.7–19+) |
DP | 3 | 2.6 (2.3–2.7) | 2 | 2.7 (2.6–2.8) |
Overall | 11 | 5.6 | 19 | 6.7 |
aMedian time to progression in months (range)